(Q38691202)

English

Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

0 references

Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

0 references

hyperparathyroidism

1 reference

based on heuristic

inferred from title

chronic renal insufficiency

1 reference

based on heuristic

inferred from title

secondary hyperparathyroidism

1 reference

based on heuristic

inferred from title

author name string

Panpan Cai

1

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Xiaohong Tang

2

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Wei Qin

3

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Ling Ji

4

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Zi Li

5

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

publication date

9 January 2016

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

International Urology and Nephrology

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

48

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

571-584

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study.

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD.

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial.

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

First impressions of cardiovascular calcification treatment in hemodialysis patients with a new dialysis fluid containing sodium thiosulphate (STS).

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Paricalcitol for secondary hyperparathyroidism in renal transplantation

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: the Hoorn study

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Mortality rates do not differ among patients prescribed various vitamin D agents

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Calcitriol resistance in hemodialysis patients with secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Pathogenesis of vascular calcification in dialysis patients

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Bone alkaline phosphatase in CKD-mineral bone disorder

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Musculoskeletal Complications After Renal Transplantation: Pathogenesis and Treatment

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial.

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-1195-6

21 January 2018

[Vitamin D in the treatment of cardiorenal syndrome in patients with chronic nephropathy].

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of oral paricalcitol on secondary hyperparathyroidism and proteinuria of kidney transplant patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vitamin D compounds for people with chronic kidney disease not requiring dialysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progression of aortic arch calcification and all-cause and cardiovascular mortality in chronic hemodialysis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised clinical study of alfacalcidol and paricalcitol

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of vitamin D receptor activator, incident cardiovascular disease and death in a cohort of hemodialysis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Effect of Active Vitamin D on Cardiovascular Outcomes in Predialysis Chronic Kidney Diseases: A Systematic Review and Meta-Analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chapter 4.1: Treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium

1 reference

https://pubmed.ncbi.nlm.nih.gov/26748501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11255-015-1195-6

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38691202&oldid=1777053305"